Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2101 in Advanced Malignancies
NCT06948539Phase 1Not yet recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2101 in solid tumor (advanced stage), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Phase II recommended doses, Dose-limiting toxicity up to 1 month and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
TQB2101
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06948539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948539.